Amosartan
1st fixed-dose combination drug introduced in Korea
Amosartan Q
Controls Hypertension and Dyslipidemia at single treatment
Amosartan Plus
Treatment to patient not adequately controlled on agent double combo FDCs
Rosuzet
Increased efficacy due to improved lipid level control
Gugutams
A novel treatment option for ED patients accompanied by BPH
Monterizine
40% of allergic rhinitis patients accompanied by asthma , 80% of asthma patients accompanied by allergic rhinitis
Hyalrheuma injection
CE certified by SGS as a class-3 medical device
FDA Grants Fast Track Designation for Hanmi LAPSTriple Agonist
Jul 22, 2020
Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program
Jun 02, 2020
Hanmi ‘Gugu Tab.’ is soon to be launched in Japan market. Marketing and Sales for the BPH treatment will be by Sandoz Japan
Feb 28, 2020